Dementia and Alzheimer Disease

The head of search and evaluation at the Alzheimer's Drug Discovery Foundation discussed the evolving role of biomarkers for diagnosis and the progress of targeted therapies in Alzheimer disease. [WATCH TIME: 5 minutes]

The chief operating officer at Linus Health talked about how brief, digitally administered cognitive assessments enable scalable, earlier identification of cognitive impairment. [WATCH TIME: 4 minutes]

The director at the National Center of Neurology and Psychiatry discussed how biomarker-driven diagnostics and antibody therapies targeting amyloid pathology may be reshaping Alzheimer disease management. [WATCH TIME: 4 minutes]

Coya Therapeutics reveals promising results for COYA 302, a potential treatment for frontotemporal dementia, showing cognitive stability and Treg enhancement.

At CTAD 2025, the director of Banner Alzheimer’s Institute discussed emerging epidemiologic and translational evidence suggesting that certain vaccines may confer protection against dementia. [WATCH TIME: 6 minutes]

The director of Cleveland Clinic's Gamme Knife Center and Head Section of Spine Tumors writes about how stereotactic radiosurgery has transformed modern neurology and neurosurgery

The associate professor at The University of Tokyo talked about how lifestyle-focused multidomain interventions, including exercise, sleep, and nutrition, may improve cognitive function. [WATCH TIME: 4 minutes]

The senior director of the Fluid Biomarker Program at Banner Health highlighted the evolving role of blood and fluid biomarkers in Alzheimer disease research and clinical practice.

A review of clinical trial and real-world data found no evidence that oral anticoagulants increase brain imaging abnormalities in patients treated with lecanemab or donanemab for early Alzheimer disease.

Review upcoming clinical trials with data readouts expected in the first half of 2026, providing updates relevant to ongoing research and clinical practice in neurology.

In a pilot study, liraglutide, a drug used for diabetes and weight-loss, significantly reduced headache days in patients with obesity and chronic or high-frequency migraine, suggesting a potential new preventive therapy.

Follow NeurologyLive's conference journey in 2026, highlighting advancements in diagnostics, treatments, and multidisciplinary care across multiple neurological conditions.

A neurologist at St Vincent's Hospital shared recently presented findings from a phase 2 study of tazbentetol, a novel synaptogenic small molecule, in mild-to-moderate Alzheimer disease. [WATCH TIME: 4 minutes]

The assistant professor at the University of Southern California discussed how intentional, community-centered recruitment strategies can improve diversity, trust, and retention in neurodegenerative studies. [WATCH TIME: 6 minutes]

As part of NeurologyLive®'s Year in Review, take a look at some of the top ongoing clinical trials in Alzheimer disease and dementia that may impact care.

Explore anticipated FDA decisions on groundbreaking neurology drugs in 2026, shaping treatment options for various neurologic conditions.

These were the most impactful FDA approval stories that were part of our coverage in 2025, brought to you as part of NeurologyLive's Year in Review.

Here's some of what is coming soon to NeurologyLive® this week.

Neurology News Network for the week ending December 27, 2025. [WATCH TIME: 4 minutes]

A look back at clinician-led features from 2025 that examine the questions, data, and decisions shaping neurologic care.

Explore the transformative buzzwords in neurology for 2025, highlighting advancements in AI, gene therapy, personalized treatment, and neuroplasticity.

Here's some of what is coming soon to NeurologyLive® this week.

GLP-1 research in neurology is on the rise, with several pivotal studies lending insights into their role.

The director of the Banner Sun Health Research Institute discussed a variety of meaningful Alzheimer disease research presented at the 2024 Clinical Trials on Alzheimer's Disease Conference (CTAD).

Neal K. Shah talked about how social robots could support emotional well-being in patients with neurologic conditions by reducing loneliness and promoting engagement in health-related activities.